SYNB:NYE-Putnam Biorevolution ETF (USD)

ETF | Others |

Last Closing

USD 33.0608

Change

+0.15 (+0.45)%

Market Cap

USD 5.43M

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on "biology revolution" companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
SOJE Southern Company (The) Series ..

-0.15 (-0.67%)

USD 65.72B
SOJE Southern Company (The) Series ..

-0.15 (-0.67%)

USD 65.72B
JEPI JPMorgan Equity Premium Income..

+0.10 (+0.17%)

USD 35.71B
JEPI JPMorgan Equity Premium Income..

+0.10 (+0.17%)

USD 35.71B
DFAC Dimensional U.S. Core Equity 2..

+0.10 (+0.29%)

USD 31.07B
DFAC Dimensional U.S. Core Equity 2..

+0.10 (+0.29%)

USD 31.07B
DTB DTE Energy Company 2020 Series

-0.32 (-1.48%)

USD 26.58B
DTB DTE Energy Company 2020 Series

-0.32 (-1.48%)

USD 26.58B
JPST JPMorgan Ultra-Short Income ET..

N/A

USD 25.99B
JPST JPMorgan Ultra-Short Income ET..

N/A

USD 25.99B

ETFs Containing SYNB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.61% 70% C- 66% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.61% 66% D+ 59% D-
Trailing 12 Months  
Capital Gain 25.36% 70% C- 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.36% 66% D+ 59% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 5.27% N/A N/A 56% F
Dividend Return 5.27% N/A N/A 48% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 6.82% N/A N/A 86% B+
Risk Adjusted Return 77.31% N/A N/A 88% B+
Market Capitalization 5.43M 12% F 4% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.